v3.25.2
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table illustrates information about segment revenues, significant segment expenses, and segment net income (loss) for the three and six months ended June 30, 2025 and 2024 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
Revenues$163,353 $109,332 $308,887 $202,093 
Less1:
Cost of product sales2,798 1,699 7,366 2,964 
Research and development
Berotralstat12,073 13,146 19,898 25,104 
Factor D Program— 5,557 1,400 16,037 
BCX177258,381 5,250 15,689 13,009 
Avoralstat8,307 4,137 15,687 8,173 
Other research, preclinical and development costs14,625 9,533 27,982 21,793 
Selling, general and administrative87,383 61,249 169,852 120,740 
Foreign currency losses, net63 84 62 135 
Interest income(2,516)(3,554)(5,540)(7,585)
Interest expense21,582 24,733 45,076 49,239 
Income tax expense1,401 172 2,127 537 
Loss on extinguishment of debt4,171 — 4,171 — 
Segment net income (loss)5,085 (12,674)5,117 (48,053)
Reconciliation of segment profit or loss:
Adjustments and reconciling items— — — — 
Consolidated net income (loss)$5,085 $(12,674)$5,117 $(48,053)
1 The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM.